Advertisement

The Effect of (−)-Epigallo-catechin-(3)-gallate on Amyloidogenic Proteins Suggests a Common Mechanism

Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 863)

Abstract

Studies on the interaction of the green tea polyphenol (−)-Epigallocatechin-3-gallate (EGCG) with fourteen disease-related amyloid polypeptides and prions Huntingtin, Amyloid-beta, alpha-Synuclein, islet amyloid polypeptide (IAPP), Sup35, NM25 and NM4, tau, MSP2, semen-derived enhancer of virus infection (SEVI), immunoglobulin light chains, beta-microglobulin, prion protein (PrP) and Insulin, have yielded a variety of experimental observations. Here, we analyze whether these observations could be explained by a common mechanism and give a broad overview of the published experimental data on the actions of EGCG. Firstly, we look at the influence of EGCG on aggregate toxicity, morphology, seeding competence, stability and conformational changes. Secondly, we screened publications elucidating the biochemical mechanism of EGCG intervention, notably the effect of EGCG on aggregation kinetics, oligomeric aggregation intermediates, and its binding mode to polypeptides. We hypothesize that the experimental results may be reconciled in a common mechanism, in which EGCG binds to cross-beta sheet aggregation intermediates. The relative position of these species in the energy profile of the amyloid cascade would determine the net effect of EGCG on aggregation and disaggregation of amyloid fibrils.

Keywords

Epigallocathechin-3-gallate (EGCG) Amyloid polypeptides Aggregation Fibrils 
This is a preview of subscription content, log in to check access.

References

  1. Abbas S, Wink M (2010) Epigallocatechin gallate inhibits beta amyloid oligomerization in Caenorhabditis elegans and affects the daf-2/insulin-like signaling pathway. Phytomedicine 17(11):902–909. doi: 10.1016/j.phymed.2010.03.008 PubMedCrossRefGoogle Scholar
  2. Andrich K, Bieschke J (2014) Aggregation in AL Amyloidosis. Biophys J 106(2):58a. doi: 10.1016/j.bpj.2013.11.401 CrossRefGoogle Scholar
  3. Bae MJ, Ishii T, Minoda K, Kawada Y, Ichikawa T, Mori T, Kamihira M, Nakayama T (2009) Albumin stabilizes (−)-epigallocatechin gallate in human serum: binding capacity and antioxidant property. Mol Nutr Food Res 53(6):709–715. doi: 10.1002/mnfr.200800274 PubMedCrossRefGoogle Scholar
  4. Beecher GR (2003) Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 133(10):3248S–3254SPubMedGoogle Scholar
  5. Berson JF, Theos AC, Harper DC, Tenza D, Raposo G, Marks MS (2003) Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. J Cell Biol 161(3):521–533. doi: 10.1083/jcb.200302072 PubMedCentralPubMedCrossRefGoogle Scholar
  6. Biancalana M, Koide S (2010) Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 1804(7):1405–1412. doi: 10.1016/j.bbapap.2010.04.001 PubMedCentralPubMedCrossRefGoogle Scholar
  7. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A 107(17):7710–7715. doi: 10.1073/pnas.0910723107 PubMedCentralPubMedCrossRefGoogle Scholar
  8. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC (1987) Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329(6139):506–512. doi: 10.1038/329506a0 PubMedCrossRefGoogle Scholar
  9. Camilleri A, Zarb C, Caruana M, Ostermeier U, Ghio S, Hogen T, Schmidt F, Giese A, Vassallo N (2013) Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochim Biophys Acta 1828(11):2532–2543. doi: 10.1016/j.bbamem.2013.06.026 PubMedCrossRefGoogle Scholar
  10. Cao P, Raleigh DP (2012) Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols. Biochemistry 51(13):2670–2683. doi: 10.1021/bi2015162 PubMedCentralPubMedCrossRefGoogle Scholar
  11. Caruana M, Högen T, Levin J, Hillmer A, Giese A, Vassallo N (2011) Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 585(8):1113–1120. doi: 10.1016/j.febslet.2011.03.046 PubMedCrossRefGoogle Scholar
  12. Chan P (2007) Efficacy and safety of green tea polyphenol in de novo Parkinson’s disease patients. http://clinicaltrials.gov/show/NCT00461942
  13. Chandrashekaran IR, Adda CG, MacRaild CA, Anders RF, Norton RS (2010) Inhibition by flavonoids of amyloid-like fibril formation by Plasmodium falciparum merozoite surface protein 2. Biochemistry 49(28):5899–5908. doi: 10.1021/bi902197x PubMedCrossRefGoogle Scholar
  14. Chandrashekaran IR, Adda CG, Macraild CA, Anders RF, Norton RS (2011) EGCG disaggregates amyloid-like fibrils formed by Plasmodium falciparum merozoite surface protein 2. Arch Biochem Biophys 513(2):153–157. doi: 10.1016/j.abb.2011.07.008 PubMedCentralPubMedCrossRefGoogle Scholar
  15. Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, Hammar M, Normark S, Hultgren SJ (2002) Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 295(5556):851–855. doi: 10.1126/science.1067484 PubMedCentralPubMedCrossRefGoogle Scholar
  16. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333–366. doi: 10.1146/annurev.biochem.75.101304.123901 PubMedCrossRefGoogle Scholar
  17. Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, Otzen DE, Vendruscolo M, Dobson CM, Knowles TP (2013) Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A 110(24):9758–9763. doi: 10.1073/pnas.1218402110 PubMedCentralPubMedCrossRefGoogle Scholar
  18. Colletier JP, Laganowsky A, Landau M, Zhao M, Soriaga AB, Goldschmidt L, Flot D, Cascio D, Sawaya MR, Eisenberg D (2011) Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci U S A 108(41):16938–16943. doi: 10.1073/pnas.1112600108 PubMedCentralPubMedCrossRefGoogle Scholar
  19. Coustou V, Deleu C, Saupe S, Begueret J (1997) The protein product of the het-s heterokaryon incompatibility gene of the fungus Podospora anserina behaves as a prion analog. Proc Natl Acad Sci U S A 94(18):9773–9778PubMedCentralPubMedCrossRefGoogle Scholar
  20. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating G (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378(9785):31–40. doi: 10.1016/S0140-6736(11)60679-X PubMedCrossRefGoogle Scholar
  21. Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, Dobson CM (2005) Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc 127(2):476–477. doi: 10.1021/ja044834j PubMedCrossRefGoogle Scholar
  22. Dragicevic N, Smith A, Lin X, Yuan F, Copes N, Delic V, Tan J, Cao C, Shytle RD, Bradshaw PC (2011) Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer’s amyloid-induced mitochondrial dysfunction. J Alzheimers Dis 26(3):507–521. doi: 10.3233/jad-2011-101629 PubMedGoogle Scholar
  23. Edmundson AB, Harris DL, Fan ZC, Guddat LW, Schley BT, Hanson BL, Tribbick G, Geysen HM (1993) Principles and pitfalls in designing site-directed peptide ligands. Proteins 16(3):246–267. doi: 10.1002/prot.340160304 PubMedCrossRefGoogle Scholar
  24. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, Legleiter J, Marsh JL, Thompson LM, Lindquist S, Muchowski PJ, Wanker EE (2006) Green tea (−)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington’s disease models. Hum Mol Genet 15(18):2743–2751. doi: 10.1093/hmg/ddl210 PubMedCrossRefGoogle Scholar
  25. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15(6):558–566. doi: 10.1038/nsmb.1437 PubMedCrossRefGoogle Scholar
  26. Falconi M, Iacovelli F, Desideri A (2013) A structural modeling approach for the understanding of initiation and elongation of ALS-linked superoxide dismutase fibrils. J Mol Model 19(9):3695–3704. doi: 10.1007/s00894-013-1896-7 PubMedCrossRefGoogle Scholar
  27. Ferreira N, Saraiva MJ, Almeida MR (2011) Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 585(15):2424–2430. doi: 10.1016/j.febslet.2011.06.030 PubMedCrossRefGoogle Scholar
  28. Ferreira N, Saraiva MJ, Almeida MR (2012a) Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: “in vivo” evidence from FAP mice models. PLoS One 7(1), e29933. doi: 10.1371/journal.pone.0029933 PubMedCentralPubMedCrossRefGoogle Scholar
  29. Ferreira N, Saraiva MJ, Almeida MR (2012b) Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy. Amyloid 19(Suppl 1):39–42. doi: 10.3109/13506129.2012.668502 PubMedCrossRefGoogle Scholar
  30. Flach K, Hilbrich I, Schiffmann A, Gartner U, Kruger M, Leonhardt M, Waschipky H, Wick L, Arendt T, Holzer M (2012) Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem 287(52):43223–43233. doi: 10.1074/jbc.M112.396176 PubMedCentralPubMedCrossRefGoogle Scholar
  31. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW (2006) Functional amyloid formation within mammalian tissue. PLoS Biol 4(1):e6. doi: 10.1371/journal.pbio.0040006 PubMedCentralPubMedCrossRefGoogle Scholar
  32. Friedemann P, Dörr J (2009) Sunphenon EGCg (Epigallocatechin-Gallate) in the early stage of Alzheimer’s disease (SUN-AK). 2009 edn. U.S. National Institutes of Health. http://clinicaltrials.gov/show/NCT00951834
  33. Gauci AJ, Caruana M, Giese A, Scerri C, Vassallo N (2011) Identification of polyphenolic compounds and black tea extract as potent inhibitors of lipid membrane destabilization by Abeta42 aggregates. J Alzheimers Dis 27(4):767–779. doi: 10.3233/JAD-2011-111061 PubMedGoogle Scholar
  34. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP (2002) A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185(6):820–827. doi: 10.1086/339342 PubMedCrossRefGoogle Scholar
  35. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T (1985) A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun 129(3):701–706. doi: 10.1016/0006-291X(85)91948-5 PubMedCrossRefGoogle Scholar
  36. Giunta B, Hou H, Zhu Y, Salemi J, Ruscin A, Shytle RD, Tan J (2010) Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice. Neurosci Lett 471(3):134–138. doi: 10.1016/j.neulet.2010.01.026 PubMedCrossRefGoogle Scholar
  37. Golde TE, Cai XD, Shoji M, Younkin SG (1993) Production of amyloid beta protein from normal amyloid beta-protein precursor (beta APP) and the mutated beta APPS linked to familial Alzheimer’s disease. Ann N Y Acad Sci 695:103–108PubMedCrossRefGoogle Scholar
  38. Graham HN (1992) Green tea composition, consumption, and polyphenol chemistry. Prev Med 21(3):334–350PubMedCrossRefGoogle Scholar
  39. Grelle G, Otto A, Lorenz M, Frank RF, Wanker EE, Bieschke J (2011) Black tea theaflavins inhibit formation of toxic amyloid-beta and alpha-synuclein fibrils. Biochemistry 50(49):10624–10636. doi: 10.1021/bi2012383 PubMedCrossRefGoogle Scholar
  40. Grey HM, Kubo RT, Colon SM, Poulik MD, Cresswell P, Springer T, Turner M, Strominger JL (1973) The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med 138(6):1608–1612PubMedCentralPubMedCrossRefGoogle Scholar
  41. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101–112. doi: 10.1038/nrm2101 PubMedCrossRefGoogle Scholar
  42. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299(5607):713–716. doi: 10.1126/science.1079589 PubMedCrossRefGoogle Scholar
  43. Hauber I, Hohenberg H, Holstermann B, Hunstein W, Hauber J (2009) The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci U S A 106(22):9033–9038. doi: 10.1073/pnas.0811827106 PubMedCentralPubMedCrossRefGoogle Scholar
  44. He Y, Cui J, Lee JC, Ding S, Chalimoniuk M, Simonyi A, Sun AY, Gu Z, Weisman GA, Wood WG, Sun GY (2011) Prolonged exposure of cortical neurons to oligomeric amyloid-beta impairs NMDA receptor function via NADPH oxidase-mediated ROS production: protective effect of green tea (−)-epigallocatechin-3-gallate. ASN Neuro 3(1), e00050. doi: 10.1042/an20100025 PubMedCentralPubMedCrossRefGoogle Scholar
  45. Hunstein W (2007) Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110(6):2216. doi: 10.1182/blood-2007-05-089243 PubMedCrossRefGoogle Scholar
  46. Ishii T, Ichikawa T, Minoda K, Kusaka K, Ito S, Suzuki Y, Akagawa M, Mochizuki K, Goda T, Nakayama T (2011) Human serum albumin as an antioxidant in the oxidation of (−)-epigallocatechin gallate: participation of reversible covalent binding for interaction and stabilization. Biosci Biotechnol Biochem 75(1):100–106. doi: 10.1271/bbb.100600 PubMedCrossRefGoogle Scholar
  47. Jarrett JT, Lansbury PT Jr (1993) Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73(6):1055–1058PubMedCrossRefGoogle Scholar
  48. Johnson KH, O’Brien TD, Betsholtz C, Westermark P (1989) Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 321(8):513–518. doi: 10.1056/NEJM198908243210806 PubMedCrossRefGoogle Scholar
  49. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300(5618):486–489. doi: 10.1126/science.1079469 PubMedCrossRefGoogle Scholar
  50. Knowles TP, Waudby CA, Devlin GL, Cohen SI, Aguzzi A, Vendruscolo M, Terentjev EM, Welland ME, Dobson CM (2009) An analytical solution to the kinetics of breakable filament assembly. Science 326(5959):1533–1537. doi: 10.1126/science.1178250 PubMedCrossRefGoogle Scholar
  51. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83(11):4044–4048PubMedCentralPubMedCrossRefGoogle Scholar
  52. Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, Hardt S, Giannitsis E, Schreiner R, Haberkorn U, Schnabel PA, Linke RP, Rocken C, Wanker EE, Dengler TJ, Altland K, Katus HA (2012) Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 101(10):805–813. doi: 10.1007/s00392-012-0463-z PubMedCentralPubMedCrossRefGoogle Scholar
  53. Lambert JD, Sang S, Yang CS (2008) N-Acetylcysteine enhances the lung cancer inhibitory effect of epigallocatechin-3-gallate and forms a new adduct. Free Radic Biol Med 44(6):1069–1074. doi: 10.1016/j.freeradbiomed.2007.12.016 PubMedCentralPubMedCrossRefGoogle Scholar
  54. Lee JW, Lee YK, Ban JO, Ha TY, Yun YP, Han SB, Oh KW, Hong JT (2009a) Green tea (−)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice. J Nutr 139(10):1987–1993. doi: 10.3945/jn.109.109785 PubMedCrossRefGoogle Scholar
  55. Lee YK, Yuk DY, Lee JW, Lee SY, Ha TY, Oh KW, Yun YP, Hong JT (2009b) (−)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency. Brain Res 1250:164–174. doi: 10.1016/j.brainres.2008.10.012 PubMedCrossRefGoogle Scholar
  56. Lee YJ, Choi DY, Yun YP, Han SB, Oh KW, Hong JT (2013) Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties. J Nutr Biochem 24(1):298–310. doi: 10.1016/j.jnutbio.2012.06.011 PubMedCrossRefGoogle Scholar
  57. LeVine H 3rd (1997) Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1–40) amyloid fibrils. Arch Biochem Biophys 342(2):306–316. doi: 10.1006/abbi.1997.0137 PubMedCrossRefGoogle Scholar
  58. LeVine H 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309:274–284PubMedGoogle Scholar
  59. Levites Y, Amit T, Mandel S, Youdim MB (2003) Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (−)-epigallocatechin-3-gallate. FASEB J 17(8):952–954. doi: 10.1096/fj.02-0881fje PubMedGoogle Scholar
  60. Li X, Zhang X, Ladiwala AR, Du D, Yadav JK, Tessier PM, Wright PE, Kelly JW, Buxbaum JN (2013) Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro. J Neurosci 33(50):19423–19433. doi: 10.1523/JNEUROSCI.2561-13.2013 PubMedCentralPubMedCrossRefGoogle Scholar
  61. Lin CL, Chen TF, Chiu MJ, Way TD, Lin JK (2009) Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation. Neurobiol Aging 30(1):81–92. doi: 10.1016/j.neurobiolaging.2007.05.012 PubMedCrossRefGoogle Scholar
  62. Linke RP (1985) Immunochemical typing of amyloid deposits after microextraction from biopsies. Appl Pathol 3(1–2):18–28PubMedGoogle Scholar
  63. Lopez del Amo JM, Fink U, Dasari M, Grelle G, Wanker EE, Bieschke J, Reif B (2012) Structural properties of EGCG-induced, nontoxic Alzheimer’s disease Abeta oligomers. J Mol Biol 421(4–5):517–524. doi: 10.1016/j.jmb.2012.01.013 PubMedCrossRefGoogle Scholar
  64. Lorenzen N, Nielsen SB, Yoshimura Y, Vad BS, Andersen CB, Betzer C, Kaspersen JD, Christiansen G, Pedersen JS, Jensen PH, Mulder FA, Otzen DE (2014) How epigallocatechin gallate can inhibit alpha-synuclein oligomer toxicity in vitro. J Biol Chem. doi: 10.1074/jbc.M114.554667 PubMedCentralGoogle Scholar
  65. Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R (2013) Molecular structure of beta-amyloid fibrils in Alzheimer’s disease brain tissue. Cell 154(6):1257–1268. doi: 10.1016/j.cell.2013.08.035 PubMedCrossRefGoogle Scholar
  66. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R (2005) 3D structure of Alzheimer’s amyloid-beta(1–42) fibrils. Proc Natl Acad Sci U S A 102(48):17342–17347. doi: 10.1073/pnas.0506723102 PubMedCentralPubMedCrossRefGoogle Scholar
  67. Maiti TK, Ghosh KS, Dasgupta S (2006) Interaction of (−)-epigallocatechin-3-gallate with human serum albumin: fluorescence, fourier transform infrared, circular dichroism, and docking studies. Proteins 64(2):355–362. doi: 10.1002/prot.20995 PubMedCrossRefGoogle Scholar
  68. Meng F, Abedini A, Plesner A, Verchere CB, Raleigh DP (2010) The flavanol (−)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry 49(37):8127–8133. doi: 10.1021/bi100939a PubMedCentralPubMedCrossRefGoogle Scholar
  69. Mereles D, Wanker EE, Katus HA (2008) Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol 97(5):341–344. doi: 10.1007/s00392-008-0649-6 PubMedCrossRefGoogle Scholar
  70. Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA (2010) Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 99(8):483–490. doi: 10.1007/s00392-010-0142-x PubMedCrossRefGoogle Scholar
  71. Merlini GPG (2013) Epigallocatechingallate (EGCG) in cardiac AL amyloidosis (EpiCardiAL). http://www.clinicaltrial.gov/ct2/show/record/NCT01511263
  72. Miyata M, Sato T, Kugimiya M, Sho M, Nakamura T, Ikemizu S, Chirifu M, Mizuguchi M, Nabeshima Y, Suwa Y, Morioka H, Arimori T, Suico MA, Shuto T, Sako Y, Momohara M, Koga T, Morino-Koga S, Yamagata Y, Kai H (2010) The crystal structure of the green tea polyphenol (−)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry 49(29):6104–6114. doi: 10.1021/bi1004409 PubMedCrossRefGoogle Scholar
  73. Nozaki A, Hori M, Kimura T, Ito H, Hatano T (2009) Interaction of polyphenols with proteins: binding of (−)-epigallocatechin gallate to serum albumin, estimated by induced circular dichroism. Chem Pharm Bull 57(2):224–228PubMedCrossRefGoogle Scholar
  74. Palhano FL, Lee J, Grimster NP, Kelly JW (2013) Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc 135(20):7503–7510. doi: 10.1021/ja3115696 PubMedCentralPubMedCrossRefGoogle Scholar
  75. Paz MA, Fluckiger R, Boak A, Kagan HM, Gallop PM (1991) Specific detection of quinoproteins by redox-cycling staining. J Biol Chem 266(2):689–692PubMedGoogle Scholar
  76. Permutt A, Chirgwin J, Giddings S, Kakita K, Rotwein P (1981) Insulin biosynthesis and diabetes mellitus. Clin Biochem 14(5):230–236PubMedCrossRefGoogle Scholar
  77. Petkova AT, Yau WM, Tycko R (2006) Experimental constraints on quaternary structure in Alzheimer’s beta-amyloid fibrils. Biochemistry 45(2):498–512. doi: 10.1021/bi051952q PubMedCentralPubMedCrossRefGoogle Scholar
  78. Popovych N, Brender JR, Soong R, Vivekanandan S, Hartman K, Basrur V, Macdonald PM, Ramamoorthy A (2012) Site specific interaction of the polyphenol EGCG with the SEVI amyloid precursor peptide PAP(248–286). J Phys Chem B 116(11):3650–3658. doi: 10.1021/jp2121577 PubMedCentralPubMedCrossRefGoogle Scholar
  79. Priller J (2011) Effects of EGCG (Epigallocatechin Gallate) in Huntington’s disease (ETON-Study). https://clinicaltrials.gov/ct2/show/NCT01357681
  80. Prince M, Albanese E, Guerchet M, Prina M (2014) World Alzheimer Report 2014 – Dementia and risk reduction – an analysis of protective and modifiable factors. World Alzheimer Report. Alzheimer’s Disease International – The global voice on dementiaGoogle Scholar
  81. Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95(23):13363–13383. doi: 10.1073/pnas.95.23.13363 PubMedCentralPubMedCrossRefGoogle Scholar
  82. Rambold AS, Miesbauer M, Olschewski D, Seidel R, Riemer C, Smale L, Brumm L, Levy M, Gazit E, Oesterhelt D, Baier M, Becker CF, Engelhard M, Winklhofer KF, Tatzelt J (2008) Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP. J Neurochem 107(1):218–229. doi: 10.1111/j.1471-4159.2008.05611.x PubMedCrossRefGoogle Scholar
  83. Redegeld FA, Nijkamp FP (2003) Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol 24(4):181–185PubMedCrossRefGoogle Scholar
  84. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25(38):8807–8814. doi: 10.1523/jneurosci.1521-05.2005 PubMedCrossRefGoogle Scholar
  85. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J (2008) Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 1214:177–187. doi: 10.1016/j.brainres.2008.02.107 PubMedCrossRefGoogle Scholar
  86. Ribeiro CA, Saraiva MJ, Cardoso I (2012) Stability of the transthyretin molecule as a key factor in the interaction with A-beta peptide–relevance in Alzheimer’s disease. PLoS One 7(9), e45368. doi: 10.1371/journal.pone.0045368 PubMedCentralPubMedCrossRefGoogle Scholar
  87. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K (1996) NMR structure of the mouse prion protein domain PrP(121–231). Nature 382(6587):180–182. doi: 10.1038/382180a0 PubMedCrossRefGoogle Scholar
  88. Roberts BE, Duennwald ML, Wang H, Chung C, Lopreiato NP, Sweeny EA, Knight MN, Shorter J (2009) A synergistic small-molecule combination directly eradicates diverse prion strain structures. Nat Chem Biol 5(12):936–946. doi: 10.1038/nchembio.246 PubMedCentralPubMedCrossRefGoogle Scholar
  89. Rodrigues CM, Sola S, Silva R, Brites D (2000) Bilirubin and amyloid-beta peptide induce cytochrome c release through mitochondrial membrane permeabilization. Mol Med 6(11):936–946PubMedCentralPubMedGoogle Scholar
  90. Saraiva MJ, Birken S, Costa PP, Goodman DS (1984) Family studies of the genetic abnormality in transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. Ann N Y Acad Sci 435:86–100PubMedCrossRefGoogle Scholar
  91. Scheraga HA, Nemethy G, Steinberg IZ (1962) The contribution of hydrophobic bonds to the thermal stability of protein conformations. J Biol Chem 237:2506–2508PubMedGoogle Scholar
  92. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90(3):549–558. doi: 10.1016/s0092-8674(00)80514-0 PubMedCrossRefGoogle Scholar
  93. Schönland SO (2013) A trial for the treatment of cardiac AL-Amyloidosis with the green tea compound epigallocatechin-3-gallate (TAME-AL). http://www.clinicaltrial.gov/ct2/show/record/NCT02015312
  94. Shorter J, Lindquist S (2004) Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 304(5678):1793–1797. doi: 10.1126/science.1098007 PubMedCrossRefGoogle Scholar
  95. Shorter J, Lindquist S (2005) Prions as adaptive conduits of memory and inheritance. Nat Rev Genet 6(6):435–450. doi: 10.1038/nrg1616 PubMedCrossRefGoogle Scholar
  96. Sinha S, Du Z, Maiti P, Klarner FG, Schrader T, Wang C, Bitan G (2012) Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01. ACS Chem Neurosci 3(6):451–458. doi: 10.1021/cn200133x PubMedCentralPubMedCrossRefGoogle Scholar
  97. Solomon A, Frangione B, Franklin EC (1982) Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest 70(2):453–460PubMedCentralPubMedCrossRefGoogle Scholar
  98. Suzuki Y, Brender JR, Hartman K, Ramamoorthy A, Marsh EN (2012) Alternative pathways of human islet amyloid polypeptide aggregation distinguished by (19)f nuclear magnetic resonance-detected kinetics of monomer consumption. Biochemistry 51(41):8154–8162. doi: 10.1021/bi3012548 PubMedCentralPubMedCrossRefGoogle Scholar
  99. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E (1998) Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol 152(2):367–372PubMedCentralPubMedGoogle Scholar
  100. Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutz Y, Weber C, Agid Y, Hirsch EC, Mandel JL (1995) Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 10(1):104–110. doi: 10.1038/ng0595-104 PubMedCrossRefGoogle Scholar
  101. Ulmer TS, Bax A, Cole NB, Nussbaum RL (2005) Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem 280(10):9595–9603. doi: 10.1074/jbc.M411805200 PubMedCrossRefGoogle Scholar
  102. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson’s disease. Biochemistry 40(26):7812–7819PubMedCrossRefGoogle Scholar
  103. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002a) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880):535–539. doi: 10.1038/416535a PubMedCrossRefGoogle Scholar
  104. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002b) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30(4):552–557. doi: 10.1042/bst0300552PubMedCrossRefGoogle Scholar
  105. Wang SH, Liu FF, Dong XY, Sun Y (2010) Thermodynamic analysis of the molecular interactions between amyloid beta-peptide 42 and (−)-epigallocatechin-3-gallate. J Phys Chem B 114(35):11576–11583. doi: 10.1021/jp1001435 PubMedCrossRefGoogle Scholar
  106. Wang SH, Dong XY, Sun Y (2012a) Effect of (−)-epigallocatechin-3-gallate on human insulin fibrillation/aggregation kinetics. Biochem Eng J 63:38–49. doi: 10.1016/j.bej.2012.02.002 CrossRefGoogle Scholar
  107. Wang SH, Dong XY, Sun Y (2012b) Thermodynamic analysis of the molecular interactions between amyloid beta-protein fragments and (−)-epigallocatechin-3-gallate. J Phys Chem B 116(20):5803–5809. doi: 10.1021/jp209406t PubMedCrossRefGoogle Scholar
  108. Wanker EE, Scherzinger E, Heiser V, Sittler A, Eickhoff H, Lehrach H (1999) Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Methods Enzymol 309:375–386PubMedGoogle Scholar
  109. Wobst HJ, Sharma A, Diamond MI, Wanker EE, Bieschke J (2015) The green tea polyphenol (−)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. 589(1):77--83. doi: 10.1016/j.febslet.2014.11.026 PubMedGoogle Scholar
  110. Wojtczak A, Luft J, Cody V (1992) Mechanism of molecular recognition. Structural aspects of 3,3′-diiodo-L-thyronine binding to human serum transthyretin. J Biol Chem 267(1):353–357PubMedGoogle Scholar
  111. Woods LA, Platt GW, Hellewell AL, Hewitt EW, Homans SW, Ashcroft AE, Radford SE (2011) Ligand binding to distinct states diverts aggregation of an amyloid-forming protein. Nat Chem Biol 7(10):730–739. doi: 10.1038/nchembio.635 PubMedCentralPubMedCrossRefGoogle Scholar
  112. Yang X, Adda CG, Keizer DW, Murphy VJ, Rizkalla MM, Perugini MA, Jackson DC, Anders RF, Norton RS (2007) A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloid-like fibrils. J Pept Sci 13(12):839–848. doi: 10.1002/psc.910 PubMedCrossRefGoogle Scholar
  113. Young LM, Cao P, Raleigh DP, Ashcroft AE, Radford SE (2014) Ion mobility spectrometry-mass spectrometry defines the oligomeric intermediates in amylin amyloid formation and the mode of action of inhibitors. J Am Chem Soc 136(2):660–670. doi: 10.1021/ja406831n PubMedCentralPubMedCrossRefGoogle Scholar
  114. Zhang T, Faraggi E, Li Z, Zhou Y (2013) Intrinsically semi-disordered state and its role in induced folding and protein aggregation. Cell Biochem Biophys 67(3):1193–1205. doi: 10.1007/s12013-013-9638-0 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Biomedical EngineeringWashington University in St. LouisSaint LouisUSA
  2. 2.Max Delbrück Center for Molecular MedicineBerlinGermany

Personalised recommendations

Cite chapter

Buy options